版本:
中国

BRIEF-Threshold Pharmaceuticals and Molecular Templates agree to combine

March 17 Threshold Pharmaceuticals Inc

* Threshold Pharmaceuticals and Molecular Templates agree to combine

* Threshold Pharmaceuticals Inc says combined company will be capitalized to support advancement of MT-3724

* Longitude Capital will invest $20 million at close of transaction

* Threshold Pharmaceuticals Inc says transaction has been approved by board of directors of both companies

* Threshold Pharma - concurrent with execution of merger agreement, Threshold made a bridge loan to Molecular Templates in principal amount of $2 million.

* Threshold Pharmaceuticals - Molecular Templates shareholders would own about 65.6 percent of combined company

* Threshold - on pro forma basis & based upon number of shares to be issued in deal, current threshold shareholders would own about 34.4 percent of combined co

* Threshold Pharmaceuticals - in event that transaction does not close by May 31, 2017, co agreed to make available further funding of up to $2 million

* Threshold Pharmaceuticals - Eric Poma, Molecular Templates' chief executive officer, will become Chief Executive Officer of combined company

* Threshold Pharmaceuticals - Longitude Capital will invest $20 million including receipt of additional equity financing commitments of $20 million

* Threshold Pharmaceuticals - following deal, board of co will consist of seven seats and will be comprised of two representatives of Molecular Templates

* Threshold Pharmaceuticals - will change its name to Molecular Templates Inc and plans to change its ticker symbol on Nasdaq Capital Market to MTEM Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐